NervGen Pharma Corp.
NGENF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $145 | $115 | $43 |
| Gross Profit | $0 | -$145 | -$115 | -$43 |
| % Margin | – | – | – | – |
| R&D Expenses | $15,726 | $8,046 | $16,613 | $6,872 |
| G&A Expenses | $9,206 | $9,730 | $6,338 | $5,938 |
| SG&A Expenses | $9,206 | $9,730 | $6,338 | $5,938 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $24,932 | $17,777 | $23,025 | $12,811 |
| Operating Income | -$24,932 | -$17,777 | -$22,824 | -$12,866 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $926 | -$4,605 | $2,303 | $85 |
| Pre-Tax Income | -$24,006 | -$22,382 | -$20,722 | -$12,727 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24,006 | -$22,382 | -$20,722 | -$12,727 |
| % Margin | – | – | – | – |
| EPS | -0.36 | -0.38 | -0.39 | -0.32 |
| % Growth | 5.3% | 2.6% | -21.9% | – |
| EPS Diluted | -0.36 | -0.38 | -0.39 | -0.32 |
| Weighted Avg Shares Out | 67,321 | 59,290 | 52,649 | 39,289 |
| Weighted Avg Shares Out Dil | 67,322 | 59,290 | 52,649 | 39,289 |
| Supplemental Information | – | – | – | – |
| Interest Income | $813 | $550 | $201 | $29 |
| Interest Expense | $0 | $0 | $515 | $0 |
| Depreciation & Amortization | $61 | $55 | $115 | $43 |
| EBITDA | -$24,871 | -$17,722 | -$22,709 | -$12,769 |
| % Margin | – | – | – | – |